Pharmacogenomic study of heart failure and candesartan response from the CHARM programme

Abstract Aims The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) programme consisted of three parallel, randomized, double‐blind clinical trials comparing candesartan with placebo in patients with heart failure (HF) categorized according to left ventricular e...

全面介紹

書目詳細資料

發表在:	ESC Heart Failure
Main Authors:	Marie‐Pierre Dubé, Olympe Chazara, Audrey Lemaçon, Géraldine Asselin, Sylvie Provost, Amina Barhdadi, Louis‐Philippe Lemieux Perreault, Ian Mongrain, Quanli Wang, Keren Carss, Dirk S. Paul, Jonathan W. Cunningham, Jean Rouleau, Scott D. Solomon, John J.V. McMurray, Salim Yusuf, Chris B. Granger, Carolina Haefliger, Simon deDenus, Jean‐Claude Tardif
格式:	Article
語言:	英语
出版:	Wiley 2022-10-01
主題:	Pharmacogenomics Candesartan CHARM Heart failure Preserved ejection fraction
在線閱讀:	https://doi.org/10.1002/ehf2.14026